Gene Therapy for Neurodegenerative Lysosomal Storage Diseases

神经退行性溶酶体贮积病的基因治疗

基本信息

项目摘要

DESCRIPTION (Provided by Applicant): Lysosomal storage diseases (LSDs) are single gene defects that result in the deficiency of a catabolic lysosomal enzyme and accumulation of one or more of its macromolecular substrates in the lysosome. GM1 gangliosidosis results from deficiency of the lysosomal enzyme beta-galactosidase (betagal), leading to progressive and fatal neurodegeneration. Human GM1 gangliosidosis occurs as three types based on disease severity and age of onset, classified as infantile, juvenile, and adult-onset forms. Gene therapy with adeno-associated viral vectors is a very promising strategy for treatment of GM1 gangliosidosis based on extraordinary preliminary results in the knockout mouse model. However, the mouse brain is 1,000-2,000 times smaller and much less complex than the brain of a human infant, requiring that results obtained in mice be reproduced in an animal with a brain size and complexity more similar to humans. The well-characterized feline model of GM1 gangliosidosis, with a brain size only 15 times smaller than a human infant, will be utilized to test therapeutic efficacy of AAV vectors in a larger and more complex brain. In addition, preliminary mouse studies employed a mouse beta-galactosidase cDNA, although AAV vectors for human clinical trials will express human betagal. Therefore, it is necessary to perform bio-equivalency studies to ensure the functionality of the human betagal cDNA before initiating human clinical trials. The experiments in this application are designed to advance AAV gene therapy toward human clinical trials through the following specific aims. In Aim 1, short-term therapeutic studies will be performed after intraparenchymal or CSF-mediated delivery of AAV vectors to the feline GM1 brain. Also, a direct comparison of human and mouse betagal will be conducted in short-term experiments in GM1 mice. In Aim 2 long-term studies of therapeutic efficacy in GM1 cats and mice will be conducted using clinical, behavioral, and biochemical assays of disease progression. Finally, Aim 3 will test the principle of in vivo selection of an AAV capsid library (molecular evolution) to identify AAV vectors with tropism for the GM1 mouse central nervous system (CNS) after intravascular (iv) infusion, and then test their therapeutic efficacy in these mice. Validation of this approach to generate AAV vectors with CNS-tropism after iv infusion will pave the way for development of such vectors for human application.
描述(由申请人提供):溶酶体胆积病(LSD)是单基因缺陷,其导致分解代谢溶酶体酶的缺乏和一种或多种其大分子底物在溶酶体中的积累。GM 1神经节苷脂沉积症是由于溶酶体酶β-半乳糖苷酶(β-galactosidase,β-galactosidase,β-galactosidase)缺乏引起的,导致进行性和致命性神经变性。人类GM 1神经节苷脂沉积症根据疾病严重程度和发病年龄分为三种类型,分为婴儿型、青少年型和成人型。腺相关病毒载体的基因治疗是一个非常有前途的策略,用于治疗GM 1神经节苷脂沉积症的基础上,在敲除小鼠模型的非凡的初步结果。然而,小鼠的大脑比人类婴儿的大脑小1,000 - 2,000倍,复杂性也低得多,因此需要在小鼠中获得的结果在具有与人类更相似的大脑大小和复杂性的动物中重现。脑大小仅比人类婴儿小15倍的GM 1神经节苷脂沉积症的良好表征的猫模型将用于测试AAV载体在更大和更复杂的脑中的治疗功效。此外,初步的小鼠研究采用小鼠β-半乳糖苷酶cDNA,尽管用于人临床试验的AAV载体将表达人β 1。因此,有必要在启动人体临床试验之前进行生物等效性研究,以确保人β 1 cDNA的功能性。本申请中的实验旨在通过以下特定目的将AAV基因治疗推向人类临床试验。在目的1中,将在脑实质内或CSF介导的AAV载体递送至猫GM 1脑后进行短期治疗研究。此外,将在GM 1小鼠的短期实验中对人和小鼠β 1进行直接比较。在目标2中,将使用疾病进展的临床、行为和生化测定在GM 1猫和小鼠中进行治疗有效性的长期研究。最后,目标3将测试AAV衣壳文库的体内选择(分子进化)的原理,以鉴定在血管内(iv)输注后对GM 1小鼠中枢神经系统(CNS)具有嗜性的AAV载体,然后测试它们在这些小鼠中的治疗功效。验证这种方法以在静脉输注后产生具有CNS向性的AAV载体将为开发用于人类应用的此类载体铺平道路。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sustained normalization of neurological disease after intracranial gene therapy in a feline model.
  • DOI:
    10.1126/scitranslmed.3007733
  • 发表时间:
    2014-04-09
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    McCurdy VJ;Johnson AK;Gray-Edwards HL;Randle AN;Brunson BL;Morrison NE;Salibi N;Johnson JA;Hwang M;Beyers RJ;Leroy SG;Maitland S;Denney TS;Cox NR;Baker HJ;Sena-Esteves M;Martin DR
  • 通讯作者:
    Martin DR
Lipidomic Evaluation of Feline Neurologic Disease after AAV Gene Therapy.
  • DOI:
    10.1016/j.omtm.2017.07.005
  • 发表时间:
    2017-09-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Gray-Edwards HL;Jiang X;Randle AN;Taylor AR;Voss TL;Johnson AK;McCurdy VJ;Sena-Esteves M;Ory DS;Martin DR
  • 通讯作者:
    Martin DR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIGUEL S ESTEVES其他文献

MIGUEL S ESTEVES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIGUEL S ESTEVES', 18)}}的其他基金

Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes
通过生物激活 MR 对比探针实时跟踪基因治疗
  • 批准号:
    10626985
  • 财政年份:
    2020
  • 资助金额:
    $ 49.31万
  • 项目类别:
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes
通过生物激活 MR 对比探针实时跟踪基因治疗
  • 批准号:
    10413250
  • 财政年份:
    2020
  • 资助金额:
    $ 49.31万
  • 项目类别:
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes
通过生物激活 MR 对比探针实时跟踪基因治疗
  • 批准号:
    10248547
  • 财政年份:
    2020
  • 资助金额:
    $ 49.31万
  • 项目类别:
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes
通过生物激活 MR 对比探针实时跟踪基因治疗
  • 批准号:
    10065373
  • 财政年份:
    2020
  • 资助金额:
    $ 49.31万
  • 项目类别:
Whole-body therapy for GM2 gangliosidoses
GM2 神经节苷脂病的全身治疗
  • 批准号:
    9241462
  • 财政年份:
    2016
  • 资助金额:
    $ 49.31万
  • 项目类别:
Whole-body therapy for GM2 gangliosidoses
GM2 神经节苷脂病的全身治疗
  • 批准号:
    9897649
  • 财政年份:
    2016
  • 资助金额:
    $ 49.31万
  • 项目类别:
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases
神经退行性溶酶体贮积病的基因治疗
  • 批准号:
    8220915
  • 财政年份:
    2010
  • 资助金额:
    $ 49.31万
  • 项目类别:
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases
神经退行性溶酶体贮积病的基因治疗
  • 批准号:
    7785865
  • 财政年份:
    2010
  • 资助金额:
    $ 49.31万
  • 项目类别:
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases
神经退行性溶酶体贮积病的基因治疗
  • 批准号:
    8017404
  • 财政年份:
    2010
  • 资助金额:
    $ 49.31万
  • 项目类别:
Development of CNS-targeted AAV vectors
CNS靶向AAV载体的开发
  • 批准号:
    8130697
  • 财政年份:
    2009
  • 资助金额:
    $ 49.31万
  • 项目类别:

相似海外基金

Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
  • 批准号:
    10755168
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
  • 批准号:
    480840
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
    Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
  • 批准号:
    10678157
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
  • 批准号:
    10744412
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
  • 批准号:
    23K07305
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
  • 批准号:
    23H02874
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
  • 批准号:
    10756652
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
  • 批准号:
    10730872
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
  • 批准号:
    10650648
  • 财政年份:
    2023
  • 资助金额:
    $ 49.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了